This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Investors See More Biotech Consolidation After Questcor Buy:

NEW YORK (TheStreet) -- An acquisition in the biotech space Monday added weight to arguments that the sector is not overvalued after the recent sell-off. And investors on readied their list of potential takeout targets mid-day even as the broader markets fell.

If $QCOR can find a buyer you have to be a snapping up quality biotech pipeline names like $VRTX $BMRN $ACAD $CLDX

-- Catalyst (@Catalystrader) Apr. 7 at 10:12 AM

Mallinckrodt (MNK - Get Report) announced before the bell that it will acquire Questcor Pharmaceuticals (QCOR) for $5.6 billion. Questcor shareholders will receive $30 per share in cash and $0.897 Mallinckrodt shares, according to the press release. The deal is a 27% premium over Questcor's Friday closing share price.

Questcor, which makes an FDA-approved multiple sclerosis treatment, rose more than 17% by 10:30 a.m. Mallinckrodt shares fell more than 3% as some investors doubted the company would quickly see a return on its investment.

Perhaps more importantly, the iShares Nasdaq Biotechnology ETF (IBB) rose 2.5% by mid-day as investors bet that the purchase would support valuations in the space and encourage more consolidation. Bullish sentiment on the biotechnology sector increased 3% to 53% after news of the acquisition, according to StockTwits' analytics.

Some cashtaggers said the Questcor buy, coupled with a correction that saw the biotech sector lose 13% in the past month, would spur larger health care companies to acquire smaller drug-makers with promising medications.

$VRTX bios beaten down pretty bad. Now is the time for buyouts. Bought some of these with that in mind. Missed $QCOR

-- James Smith (@creativeflood) Apr. 7 at 10:07 AM

Vertex Pharmaceuticals (VRTX) was one of the most discussed names on investors' potential acquisition short lists. It has a $15.72 billion market cap and two FDA-approved drugs. One medication, Kalydeco, is intended to treat cystic fibrosis. The other, INCIVEK, is prescribed for hepatitis C sufferers. The stock rose more than 1% Monday morning. Biomarin Pharmaceuticals (BMRN) was another mentioned company. The stock traded at near flat by 11a.m. though some said that the $9 billion company was an attractive target. The company has five drugs on the market and another seven in some phase of clinical trials. The stock is down 18% in the past month.

Traded $BMRN many times & profited..this huge drop is a market gift...May drop more, but watching to buy back..great drug pipeline.

-- Chris (@Piggybank) Apr. 5 at 12:16 PM

At the time of publication, the author held no positions in any of the stocks mentioned.

This article represents the opinion of a contributor and not necessarily that of TheStreet or its editorial staff.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
MNK $56.40 -7.27%
QCOR $93.60 1.65%
AAPL $92.72 -0.56%
FB $119.49 1.43%
GOOG $711.12 1.38%


Chart of I:DJI
DOW 17,740.63 +79.92 0.45%
S&P 500 2,057.14 +6.51 0.32%
NASDAQ 4,736.1550 +19.0610 0.40%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs